Zhejiang Medicine : prévoit de scinder sa filiale Xinma Bio pour une introduction en bourse sur le marché principal de la HKEX

2026-04-10 10:19:22

Création du résumé en cours

Mars Finance News April 10 - Zhejiang Medicine announced that the company disclosed a plan to spin off its subsidiary Zhejiang Xinma Biopharmaceutical Co., Ltd. for listing on the Main Board of the Hong Kong Stock Exchange. After the completion of this spin-off, Zhejiang Medicine is expected to maintain control over Xinma Biopharmaceutical, and the financial condition and profitability of Xinma Biopharmaceutical will still be reflected in the company’s consolidated financial statements. Xinma Biopharmaceutical mainly focuses on innovative biopharmaceutical research and development, with core pipelines including ADC drugs such as ARX788. The purpose of this spin-off is to streamline the business structure, unlock valuation potential of the innovative drug sector, expand financing channels, and enhance overall competitiveness. (Company Announcement)

Voir l'original

Cette page peut inclure du contenu de tiers fourni à des fins d'information uniquement. Gate ne garantit ni l'exactitude ni la validité de ces contenus, n’endosse pas les opinions exprimées, et ne fournit aucun conseil financier ou professionnel à travers ces informations. Voir la section Avertissement pour plus de détails.